Pediatric COVID-19 Vaccines: CDC’s Recommendations for Pfizer BioNTech COVID-19 Vaccine Primary Series in Children 5–11 Years Old

Posted almost 4 years ago by Meredith Roberts

Overview

The Centers for Disease Control and Prevention will provide an overview of its recommendations and clinical considerations for administering the Pfizer BioNTech COVID-19 vaccination primary series in children aged 5–11 years old.

If you are unable to attend the live COCA Call, the recording will be available for viewing on the COCA Call webpage a few hours after the live event ends.

The slide set will be available under Call Materials on the COCA Call webpage.

Continuing Education will not be offered for this COCA Call.

Registration is not required.

Date: Thursday, November 4, 2021

Time: 2:00 pm - 3:00 pm (ET)

A few minutes before the webinar starts,

please click on the Zoom link below to join: https://www.zoomgov.com/j/1610046996

Or One tap mobile:

US: +16692545252,,1610046996#,,,,*767827# or +16468287666,,1610046996#,,,,*767827

Or Telephone:

US: +1 669 254 5252 or +1 646 828 7666

or +1 551 285 1373 or +1 669 216 1590

Webinar ID: 161 004 6996

Passcode: 767827

International numbers available:
https://www.zoomgov.com/u/ab2UFvSsCs

COCA Call Objectives

At the conclusion of the session, the participant will be able to accomplish the following—

Cite background information on the topic covered during the presentation.
Discuss CDC’s role in the topic covered during the presentation.
Describe the topic’s implications for clinicians.
Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats.
Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an interprofessional team of healthcare providers.

Speakers

Sara Oliver, MD, MSPH

LCDR, U.S. Public Health Service

Co-lead, Advisory Committee for Immunization Practices COVID-19 Vaccines Work Group

Vaccine Task Force

COVID-19 Response

Centers for Disease Control and Prevention

Kate Woodworth, MD, MPH, FAAP

Advisory Committee for Immunization Practices COVID-19 Vaccines Work Group

Vaccine Task Force

COVID-19 Response

Centers for Disease Control and Prevention

Kevin Chatham-Stephens, MD, MPH, FAAP

CDR, U.S. Public Health Service

Pediatric Vaccine Readiness and Implementation Lead

Vaccine Task Force

COVID-19 Response

Centers for Disease Control and Prevention

The Emergency Risk Communication Branch in the Division of Emergency Operations, Center for Preparedness and Response is responsible for the management of all COCA products.

For information about this update or other clinical issues, or to send your feedback, please contact us at coca@cdc.gov